Trial · NCT02683239
Results by group181
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 181
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Any Treatment-Emergent Adverse Event (TEAE) | Fasinumab-matching Placebo Q4W/Q8W | 1055 | Participants | ||
| Number of Participants With Any Treatment-Emergent Adverse Event (TEAE) | Fasinumab 1 mg SC Q8W | 840 | Participants | ||
| Number of Participants With Any Treatment-Emergent Adverse Event (TEAE) | Fasinumab 1 mg SC Q4W | 885 | Participants | ||
| Number of Participants With Any Treatment-Emergent Adverse Event (TEAE) | Fasinumab 3 mg SC Q4W | 185 | Participants | ||
| Number of Participants With Any Treatment-Emergent Adverse Event (TEAE) | Fasinumab 6 mg SC Q8W | 1487 | Participants | ||
| Number of Participants With Any Treatment-Emergent Adverse Event (TEAE) | Fasinumab 6 mg SC Q4W | 93 | Participants | ||
| Number of Participants With Any Treatment-Emergent Adverse Event (TEAE) | Fasinumab 9 mg SC Q4W | 92 | Participants | ||
| Number of Participants With Any Serious TEAE | Fasinumab-matching Placebo Q4W/Q8W | 82 | Participants | ||
| Number of Participants With Any Serious TEAE | Fasinumab 1 mg SC Q8W | 57 | Participants | ||
| Number of Participants With Any Serious TEAE | Fasinumab 1 mg SC Q4W | 70 | Participants | ||
| Number of Participants With Any Serious TEAE | Fasinumab 3 mg SC Q4W | 13 | Participants | ||
| Number of Participants With Any Serious TEAE | Fasinumab 6 mg SC Q8W | 107 | Participants | ||
| Number of Participants With Any Serious TEAE | Fasinumab 6 mg SC Q4W | 5 | Participants | ||
| Number of Participants With Any Serious TEAE | Fasinumab 9 mg SC Q4W | 3 | Participants | ||
| Number of Participants With Any Adverse Event (AE) up to Week 72 | Fasinumab-matching Placebo Q4W/Q8W | 1112 | Participants | ||
| Number of Participants With Any Adverse Event (AE) up to Week 72 | Fasinumab 1 mg SC Q8W | 867 | Participants | ||
| Number of Participants With Any Adverse Event (AE) up to Week 72 | Fasinumab 1 mg SC Q4W | 902 | Participants | ||
| Number of Participants With Any Adverse Event (AE) up to Week 72 | Fasinumab 3 mg SC Q4W | 192 | Participants | ||
| Number of Participants With Any Adverse Event (AE) up to Week 72 | Fasinumab 6 mg SC Q8W | 1570 | Participants | ||
| Number of Participants With Any Adverse Event (AE) up to Week 72 | Fasinumab 6 mg SC Q4W | 106 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02683239/results